Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06606613 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cross-linked Hyaluronic Acid/dextranomer for the Treatment of Stress Urinary Incontinence

Study acronym: (CLHA/Dx)
StatusUnknown
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 26, 2024 (before its estimated March 10, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
  2. Phase: Phase 3 to Phase 2
    • Eligibility criteria shortened, about 10 words
    • Site details revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The investigators aimed to evaluate the effectiveness and safety of intraurethral cross-linked hyaluronic acid/dextranomer (CLHA/Dx) injection for the treatment of stress urinary incontinence (SUI) in women.
Trial Details
NCT Number NCT06606613
Lead Sponsor Izmir Bakircay University
Conditions
(from sponsor)		 Urinary Stress Incontinence (SI)
Related terms Urinary Incontinence, Stress
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov